Vikram C. Gorantla, MD, discusses an analysis of T-DXd vs tucatinib plus trastuzumab and capecitabine in HER2-positive breast cancer with brain metastases.
Back
Dr Gorantla on a Real-World Study of HER2-Directed Breast Cancer Therapy
Dr Gorantla on a Real-World Study of HER2-Directed Breast Cancer Therapy
Episodes
All
All
Vikram C. Gorantla, MD, notes real-world treatment patterns and outcomes with second-line T-DXd vs tucatinib-based therapy in HER2-positive breast cancer.
Vikram C. Gorantla, MD, discusses real-world treatment patterns with T-DXd vs tucatinib-based therapy in HER2-positive breast cancer with brain metastases.
Vikram C. Gorantla, MD, discusses future directions for sequencing available therapies for patients with breast cancer who develop brain metastases.
Advertisement
Advertisement
Trending on OncLive
1
Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
2
T-DXd Improves PFS in First-Line HER2-Mutant NSCLC
3
Five Under 5: Top Oncology Videos for the Week of 8/9
4
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
5